Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA4 | P22748 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24040332 | 0.92 | MEN1 (0.41) | CA2KMT2AMEN1NCF1TSHR | |
| SCHEMBL20017289 | 0.88 | MEN1 (0.41) | CA2KMT2AMEN1NCF1TSHR | |
| SCHEMBL12589997 | 0.87 | TSHR (0.42) | CA2KMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL21172350 | 0.87 | MEN1 (0.38) | CA2KMT2AMEN1NCF1TSHR | |
| SCHEMBL24838579 | 0.87 | TSHR (0.39) | KMT2AMEN1TSHRRECQLALDH1A1 | |
| SCHEMBL12730446 | 0.87 | TSHR (0.42) | CA2KMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL15750359 | 0.87 | HDAC3 (0.33) | CA2KMT2AMEN1NCF1TSHR | |
| SCHEMBL13018276 | 0.86 | GLP1R (0.36) | TSHRRECQLCYP2C19 | |
| SCHEMBL15765871 | 0.85 | MEN1 (0.37) | CA2KMT2AMEN1NCF1TSHR | |
| SCHEMBL1257485 | 0.85 | GLP1R (0.41) | CA2KMT2AMEN1NCF1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179467-B2 | Exenatide modifier and use thereof | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179467-B2 | Exenatide modifier and use thereof | GLP1R, GCGR, GIPR | CA2 4646/4885KMT2A 3214/4885MEN1 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.